BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...

Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.

The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective ...

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital. Results for the ...

View all available purchase options and get full access to this article. Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian ...

Amyloid fibrils appear in many neurodegenerative diseases, and scientists are eager to understand how they form and spread. But amyloids—clumped aggregations of misfolded proteins—can be ...

Cardiac amyloidosis is becoming increasingly recognized as an etiology for heart failure (HF). Most cases of amyloid cardiomyopathy will fall into one of two categories: light-chain amyloid (AL) ...